U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H27NO.BrH
Molecular Weight 402.368
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETHYBENZTROPINE HYDROBROMIDE

SMILES

Br.CCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C3=CC=CC=C3)C4=CC=CC=C4

InChI

InChIKey=VDVKOVNNSSRFGV-QYESKELBSA-N
InChI=1S/C22H27NO.BrH/c1-2-23-19-13-14-20(23)16-21(15-19)24-22(17-9-5-3-6-10-17)18-11-7-4-8-12-18;/h3-12,19-22H,2,13-16H2,1H3;1H/t19-,20+,21+;

HIDE SMILES / InChI

Molecular Formula BrH
Molecular Weight 80.912
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C22H27NO
Molecular Weight 321.4559
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Ethybenzatropine (Ponalid) is an anticholinergic and antihistaminergic drug. It was used as an antiparkinsonian agent. A significant increase in the duration of action of levodopa-induced improvement in parkinsonian symptoms was observed following the administration of ethybenzatropine. Ethybenzatropine also improved, or tended to improve the duration and seventy of onset and end-of-dose levodopa-induced dyskinesias. Thus when levodopa is administered together with etybenzatropine, its length of action on parkinsonian symptoms is prolonged.

Approval Year

PubMed

PubMed

TitleDatePubMed
Effects of etybenzatropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson's disease.
1989

Sample Use Guides

Nine patients with Parkinson’s disease: Levodopa was given orally together with a peripheral DOPA-decarboxylase inhibitor at the usual effective morning dosage for each patient. The same dose of levodopa was administered the next day in addition to ethybenzatropine, 5 mg given i.v. Ethybenzatropine was administered between 0 and 15 min after the first dose of levodopa
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Sat Dec 16 07:46:46 GMT 2023
Edited
by admin
on Sat Dec 16 07:46:46 GMT 2023
Record UNII
KK24PH7EPQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETHYBENZTROPINE HYDROBROMIDE
MI  
Common Name English
ETHYLBENZTROPINE-HYDROBROMIDE
Common Name English
ETYBENZATROPINE HYDROBROMIDE
Common Name English
8-AZABICYCLO(3.2.1)OCTANE, 3-(DIPHENYLMETHOXY)-8-ETHYL-, HYDROBROMIDE, ENDO-
Common Name English
ETHYBENZTROPINE HYDROBROMIDE [MI]
Common Name English
Etybenzatropine bromide [WHO-DD]
Common Name English
8-AZABICYCLO(3.2.1)OCTANE, 3-(DIPHENYLMETHOXY)-8-ETHYL-, HYDROBROMIDE, (3-ENDO)-
Common Name English
ETYBENZATROPINE BROMIDE
WHO-DD  
Common Name English
1.ALPHA.H,5.ALPHA.H-NORTROPANE, 3.ALPHA.-(DIPHENYLMETHOXY)-8-ETHYL-, HYDROBROMIDE
Common Name English
Code System Code Type Description
MERCK INDEX
m5080
Created by admin on Sat Dec 16 07:46:46 GMT 2023 , Edited by admin on Sat Dec 16 07:46:46 GMT 2023
PRIMARY Merck Index
PUBCHEM
71587064
Created by admin on Sat Dec 16 07:46:46 GMT 2023 , Edited by admin on Sat Dec 16 07:46:46 GMT 2023
PRIMARY
SMS_ID
100000087499
Created by admin on Sat Dec 16 07:46:46 GMT 2023 , Edited by admin on Sat Dec 16 07:46:46 GMT 2023
PRIMARY
CAS
24815-25-6
Created by admin on Sat Dec 16 07:46:46 GMT 2023 , Edited by admin on Sat Dec 16 07:46:46 GMT 2023
PRIMARY
EVMPD
SUB02049MIG
Created by admin on Sat Dec 16 07:46:46 GMT 2023 , Edited by admin on Sat Dec 16 07:46:46 GMT 2023
PRIMARY
FDA UNII
KK24PH7EPQ
Created by admin on Sat Dec 16 07:46:46 GMT 2023 , Edited by admin on Sat Dec 16 07:46:46 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY